Heartflow Inc. Receives FDA 510(k) Clearance for Next Generation Heartflow Plaque Analysis Platform, Secures Nationwide Cigna Coverage

Reuters

Sep 23

Heartflow Inc. Receives FDA 510(k) Clearance for Next Generation Heartflow Plaque Analysis Platform, Secures Nationwide Cigna Coverage

Heartflow Inc. has announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Next Generation Heartflow Plaque Analysis platform. The newly approved technology features an updated algorithm, expanded nomogram, and advanced 3D color-coded visualization of plaque type, volume, and distribution. This advancement will enable clinicians to make more informed care decisions with ease. Additionally, Heartflow Plaque Analysis will be covered by Cigna Health Plans nationwide starting in October, marking a significant step in making this AI-powered technology accessible to a broader range of patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartflow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9533250-en) on September 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569303627"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569303627\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569303627?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569303627","market":"us","top_or_hot":-1,"title":"Heartflow Inc. Receives FDA 510(k) Clearance for Next Generation Heartflow Plaque Analysis Platform, Secures Nationwide Cigna Coverage","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Heartflow Inc. Receives FDA 510(k) Clearance for Next Generation Heartflow Plaque Analysis Platform, Secures Nationwide Cigna Coverage\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Heartflow Inc. has announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Next Generation Heartflow Plaque Analysis platform. The newly approved technology features an updated algorithm, expanded nomogram, and advanced 3D color-coded visualization of plaque type, volume, and distribution. This advancement will enable clinicians to make more informed care decisions with ease. Additionally, Heartflow Plaque Analysis will be covered by Cigna Health Plans nationwide starting in October, marking a significant step in making this AI-powered technology accessible to a broader range of patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartflow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9533250-en) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heartflow Inc. Receives FDA 510(k) Clearance for Next Generation Heartflow Plaque Analysis Platform, Secures Nationwide Cigna Coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeartflow Inc. Receives FDA 510(k) Clearance for Next Generation Heartflow Plaque Analysis Platform, Secures Nationwide Cigna Coverage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-23 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Heartflow Inc. Receives FDA 510(k) Clearance for Next Generation Heartflow Plaque Analysis Platform, Secures Nationwide Cigna Coverage\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Heartflow Inc. has announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Next Generation Heartflow Plaque Analysis platform. The newly approved technology features an updated algorithm, expanded nomogram, and advanced 3D color-coded visualization of plaque type, volume, and distribution. This advancement will enable clinicians to make more informed care decisions with ease. Additionally, Heartflow Plaque Analysis will be covered by Cigna Health Plans nationwide starting in October, marking a significant step in making this AI-powered technology accessible to a broader range of patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartflow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9533250-en) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1261432733.SGD","symbol_name":"Fidelity World A-ACC-SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL6SJmbZ:1","article_id":"2569303627","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569303627","pubTimestamp":1758571514,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Heartflow Inc. Receives FDA 510 Clearance for Next Generation Heartflow Plaque Analysis Platform, Secures Nationwide Cigna Coverage. Heartflow Inc. has announced that it has received U.S. Food and Drug Administration  510 clearance for its Next Generation Heartflow Plaque Analysis platform. The newly approved technology features an updated algorithm, expanded nomogram, and advanced 3D color-coded visualization of plaque type, volume, and distribution. This advancement will enable clinicians to make more informed care decisions with ease. Additionally, Heartflow Plaque Analysis will be covered by Cigna Health Plans nationwide starting in October, marking a significant step in making this AI-powered technology accessible to a broader range of patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4167":"医疗保健技术","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4588":"碎股","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4196":"保健护理服务","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4585":"ETF&股票定投概念","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","HTFL":"HeartFlow Inc","CI":"信诺保险","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD"},"translate_title":"Heartflow Inc.下一代Heartflow斑块分析平台获得FDA 510(k)许可，确保Cigna覆盖全国","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CI":0.9,"HTFL":0.9,"NDAQ":0.9},"content_text":"Heartflow Inc. Receives FDA 510(k) Clearance for Next Generation Heartflow Plaque Analysis Platform, Secures Nationwide Cigna Coverage\n    \n\n        Heartflow Inc. has announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Next Generation Heartflow Plaque Analysis platform. The newly approved technology features an updated algorithm, expanded nomogram, and advanced 3D color-coded visualization of plaque type, volume, and distribution. This advancement will enable clinicians to make more informed care decisions with ease. Additionally, Heartflow Plaque Analysis will be covered by Cigna Health Plans nationwide starting in October, marking a significant step in making this AI-powered technology accessible to a broader range of patients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartflow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9533250-en) on September 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}